S 531011
Alternative Names: S-531011Latest Information Update: 21 Nov 2021
At a glance
- Originator Shionogi
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 12 Nov 2021 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA, Japan (IV) (NCT05101070) (Shionogi pipeline, November 2021)
- 12 Nov 2021 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA, Japan (IV) (NCT05101070)(Shionogi pipeline, November 2021)
- 10 Nov 2021 Shionogi plans a phase Ib/II aCCeleR8-001 trial (Monotherapy, Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Japan and USA in November 2021 (IV) (NCT05101070)